These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

208 related items for PubMed ID: 23676603

  • 1. Successful treatment of class IV+V lupus nephritis with combination therapy of high-dose corticosteroids, tacrolimus and intravenous cyclophosphamide.
    Kurasawa T, Nagasawa H, Nishi E, Takei H, Okuyama A, Kondo T, Nishimura K, Sakai R, Shibata A, Chino K, Ogawa H, Ito T, Amano K, Kato H.
    Intern Med; 2013; 52(10):1125-30. PubMed ID: 23676603
    [Abstract] [Full Text] [Related]

  • 2. Induction therapy with low-dose intravenous cyclophosphamide, oral mizoribine, and steroids for severe lupus nephritis in children.
    Fujinaga S, Kaneko K, Ohtomo Y, Murakami H, Takada M, Akashi S, Hira M, Yamashiro Y.
    Pediatr Nephrol; 2005 Oct; 20(10):1500-3. PubMed ID: 16021476
    [Abstract] [Full Text] [Related]

  • 3. Multitarget therapy of mycophenolate mofetil and cyclosporine A for induction treatment of refractory lupus nephritis.
    Jesus D, Rodrigues M, da Silva JAP, Inês L.
    Lupus; 2018 Jul; 27(8):1358-1362. PubMed ID: 29448882
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of multitarget therapy with mizoribine and tacrolimus for systemic lupus erythematosus with or without active nephritis.
    Nomura A, Shimizu H, Kishimoto M, Suyama Y, Rokutanda R, Ohara Y, Yamaguchi K, Okada M.
    Lupus; 2012 Nov; 21(13):1444-9. PubMed ID: 22917589
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of multitarget therapy with cyclophosphamide and tacrolimus for lupus nephritis: a prospective, single-arm, single-centre, open label pilot study in Japan.
    Sakai R, Kurasawa T, Nishi E, Kondo T, Okada Y, Shibata A, Nishimura K, Chino K, Okuyama A, Takei H, Nagasawa H, Amano K.
    Lupus; 2018 Feb; 27(2):273-282. PubMed ID: 28683654
    [Abstract] [Full Text] [Related]

  • 6. Mycophenolate mofetil or tacrolimus compared with intravenous cyclophosphamide in the induction treatment for active lupus nephritis.
    Li X, Ren H, Zhang Q, Zhang W, Wu X, Xu Y, Shen P, Chen N.
    Nephrol Dial Transplant; 2012 Apr; 27(4):1467-72. PubMed ID: 21917733
    [Abstract] [Full Text] [Related]

  • 7. Intravenous cyclophosphamide pulse therapy in Japanese children with systemic lupus erythematosus.
    Igarashi T, Igarashi T, Shimizu A, Itoh Y.
    J Nippon Med Sch; 2013 Apr; 80(5):396-400. PubMed ID: 24189359
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of mycophenolate mofetil in Japanese patients with systemic lupus erythematosus.
    Kawazoe M, Kaneko K, Yamada Z, Masuoka S, Mizutani S, Yamada S, Shikano K, Sato H, Kaburaki M, Muraoka S, Kawai S, Nanki T.
    Clin Rheumatol; 2019 Jun; 38(6):1571-1578. PubMed ID: 30778862
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Mizoribine, tacrolimus, and corticosteroid combination therapy successfully induces remission in patients with lupus nephritis.
    Kagawa H, Hiromasa T, Hara T, Takaki A, Yamanaka R, Sada KE, Makino H.
    Clin Exp Nephrol; 2012 Oct; 16(5):760-6. PubMed ID: 22492013
    [Abstract] [Full Text] [Related]

  • 11. Comparative clinical prospective therapeutic study between cyclophosphamide, cyclosporine and azathioprine in the treatment of lupus nephritis.
    El-Sehemy MS, Al-Saaran AM, Baddour NM, Adam AG, Moez PE.
    Egypt J Immunol; 2006 Oct; 13(1):39-52. PubMed ID: 17974149
    [Abstract] [Full Text] [Related]

  • 12. Mizoribine versus mycophenolate mofetil or intravenous cyclophosphamide for induction treatment of active lupus nephritis.
    Feng X, Gu F, Chen W, Liu Y, Wei H, Liu L, Yin S, Da Z, Sun L.
    Chin Med J (Engl); 2014 Oct; 127(21):3718-23. PubMed ID: 25382325
    [Abstract] [Full Text] [Related]

  • 13. Pilot 24 month study to compare mycophenolate mofetil and tacrolimus in the treatment of membranous lupus nephritis with nephrotic syndrome.
    Yap DY, Yu X, Chen XM, Lu F, Chen N, Li XW, Tang CS, Chan TM.
    Nephrology (Carlton); 2012 May; 17(4):352-7. PubMed ID: 22295934
    [Abstract] [Full Text] [Related]

  • 14. Comparison of efficacy of continuous mycophenolate mofetil with sequential cyclophosphamide and tacrolimus as maintenance therapy for lupus nephritis.
    Kawazoe M, Nanki T.
    Lupus; 2024 Apr; 33(4):319-327. PubMed ID: 38232223
    [Abstract] [Full Text] [Related]

  • 15. Effect of Tacrolimus vs Intravenous Cyclophosphamide on Complete or Partial Response in Patients With Lupus Nephritis: A Randomized Clinical Trial.
    Zheng Z, Zhang H, Peng X, Zhang C, Xing C, Xu G, Fu P, Ni Z, Chen J, Xu Z, Zhao MH, Li S, Huang X, Miao L, Chen X, Liu B, He Y, Li J, Liu L, Kadeerbai H, Liu Z, Liu Z.
    JAMA Netw Open; 2022 Mar 01; 5(3):e224492. PubMed ID: 35353167
    [Abstract] [Full Text] [Related]

  • 16. Cost-effectiveness of tacrolimus for the treatment of moderate-to-severe lupus nephritis in China.
    Kim S, Reen Ooi AY, Stephens T, Jiang H.
    J Comp Eff Res; 2019 Oct 01; 8(13):1125-1141. PubMed ID: 31580156
    [Abstract] [Full Text] [Related]

  • 17. Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up.
    Mok CC, Ying KY, Yim CW, Siu YP, Tong KH, To CH, Ng WL.
    Ann Rheum Dis; 2016 Jan 01; 75(1):30-6. PubMed ID: 25550339
    [Abstract] [Full Text] [Related]

  • 18. Multitarget therapy versus intravenous cyclophosphamide in the induction treatment of lupus nephritis: a metaanalysis of randomized controlled trials.
    Deng J, Luo L, Zhu L, Xie H, xie H.
    Turk J Med Sci; 2018 Oct 31; 48(5):901-910. PubMed ID: 30384552
    [Abstract] [Full Text] [Related]

  • 19. Treatment of severe lupus nephritis: the new horizon.
    Chan TM.
    Nat Rev Nephrol; 2015 Jan 31; 11(1):46-61. PubMed ID: 25421826
    [Abstract] [Full Text] [Related]

  • 20. Comparison of disease activity between tacrolimus and mycophenolate mofetil in lupus nephritis: a randomized controlled trial.
    Kamanamool N, Ingsathit A, Rattanasiri S, Ngamjanyaporn P, Kasitanont N, Chawanasuntorapoj R, Pichaiwong W, Anutrakulchai S, Sangthawan P, Ophascharoensuk V, Avihingsanon Y, Sumethkul V.
    Lupus; 2018 Apr 31; 27(4):647-656. PubMed ID: 29105558
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.